Search PubMed⌕ Search

Biomedical subjects

Steven L. Galetta

Publications and source records attributed to Steven L. Galetta.

3 recordsLinked to original sources

Functional Visual Loss.

Patients who present with visual loss that cannot be explained by organic lesions represent a wide spectrum of patients from those with no physiologic problem to those patients who have a true underlying condition. Regardless of where a patient falls within this spectrum, all patients need to be approached with a clinical evaluation to ensure that no underlying physiologic deficit exists. After excluding organic causes with appropriate examination and testing, a patient's visual loss still should not be labeled as functional until it is proven that they can see better than they claim to see. Only after convincingly demonstrating better vision can the physician begin to consider treatment options to help the patient's vision recover. Although functional visual loss places the physician in an unusual adversarial position of refuting a patient's symptoms, exposing the patient in a confrontational manner rarely helps. Instead, an approach that allows patients to resolve the symptoms on their own through reassurance and support often leads to successful restoration of vision. Reassurance that their condition is not serious, and may recover with time, allows patients to slowly admit their vision is improving without ever suggesting that the concern and medical attention they sought was unwarranted.

Journal Article↗

Orbital Inflammatory Disease.

Idiopathic orbital inflammatory syndrome (IOIS) is a diagnosis of exclusion, requiring an evaluation to rule out other causes of orbital disease. Orbital MRI is the test of choice, but serologic studies are necessary to exclude a systemic etiology. Biopsy is usually not indicated at presentation, as the risk of causing damage to vital structures within the orbit outweighs the benefits. Patients unresponsive to therapy or those with multiple recurrences should be biopsied. The first-line treatment is corticosteroids, which may be tapered over several months. Although data is limited, radiotherapy is indicated for patients who fail to respond to steroids, or who have a rapidly progressive course. For those patients who are refractory to both corticosteroids and radiotherapy, anecdotal reports have supported the use of chemotherapeutic agents such as cyclophosphamide, methotrexate, and cyclosporine.

Journal Article↗

Ocular Myasthenia Gravis.

Treatment decisions for ocular myasthenia gravis (OMG) should be based on symptomatology. Local, nonpharmacologic treatment of ptosis or diplopia is successful in relatively few patients, and the majority of patients require drug therapy for satisfactory resolution of their symptoms. Response to anticholinesterase agents is variable, but should always be used as the first-line agent or adjunctive therapy in the treatment of OMG. It is unknown whether early treatment of OMG with corticosteroids or other immunosuppressive agents prevents or delays the development of generalized myasthenia, although some observations support this speculation. Corticosteroids are usually necessary for adequate improvement of ophthalmoplegia or ptosis. Surgical correction of ptosis or ocular motility deficits is not recommended for most patients with OMG, because of the fluctuating nature of the deficits and the high rate of recurrent deficits following surgery. All patients with OMG should be screened for the presence of thymus tumors, and thymectomy is recommended for all patients with a thymoma. Some patients with OMG who do not harbor a thymus tumor may also benefit from thymectomy.

Journal Article↗